Catalyzing Effective Immune Responses In Immunologically "Cold" Tumors

Catalyzing Effective Immune Responses In Immunologically "Cold" Tumors

Our Approach

Rapidly Translate Innovative Research

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

Develop a Pipeline Optimized for Combination

Immunogenesis is focused on developing a pipeline of drugs that, in combination, will synergize to address the critical ingredients for effective immunity against "cold" tumors: 1) Generation of sufficient anti-tumor T cells; 2) protection and expansion of those cells in the tumor; and 3) reduction in hostile tumor metabolism.

Conduct Biomarker-Driven Clinical Trials

We plan our clinical studies to treat patient populations most likely to experience optimal benefit. Further, we leverage novel imaging, and cellular and molecular analysis to understand the mechanisms driving response versus resistance.

Company Highlights

ImmunoGenesis Team

Executive Management

Michael Curran, PhD
Founder and SAB Head
James Barlow
William Tanner, PhD
Annemarie Moseley, MD, PhD
Acting Chief Medical Officer
Federica Pericle, PhD, MBA
Consultant Chief Scientific Officer

Board of Directors

James Barlow
CEO | Board Member
Robert Stein
Board Member
Clifford Stocks
Board Member
Ted Koutouzis
Board Member


Darryl Patrick

Investors & Media

ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer

June 16, 2021

Data reported in Clinical Cancer Research support the efficacy of evofosfamide in combination with checkpoint inhibition in advanced, immunologically “cold” tumors.

ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline

December 8, 2020

ImmunoGenesis, Inc., a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically cold cancers such as prostate, colorectal and pancreatic cancer, today announced that it has acquired the rights to the hypoxia-reducing agent evofosfamide.

ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)

August 24, 2020

ImmunoGenesis, Inc. has been awarded a $15.5 M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance development of IMGS-001, the company’s dual specific Checkpoint Inhibitor and Tumor Microenvironment (TME) remodeling agent.